Clinical Trials
1,041 trialsCyto-KIK
Columbia University
Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial
Jonsson Comprehensive Cancer Center
TTV ccRCC
Regina Elena Cancer Institute
CANIQOL
Centre Francois Baclesse
VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Mayo Clinic
SABR for Renal Tumors
University Health Network, Toronto
Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma
Yale University
ALTER-UC-011
Tianjin Medical University Cancer Institute and Hospital
Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer
University of Southern California
Perfusion Magnetic Resonance Imaging in Diagnosing Patients With Kidney Tumors
Rutgers, The State University of New Jersey
TTBF
University of California, San Francisco
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Alliance for Clinical Trials in Oncology
"Embolization Before Ablation of Renal Cell Carcinoma (EMBARC)"
University of Alabama at Birmingham
STRIKE
Alliance for Clinical Trials in Oncology
Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery
M.D. Anderson Cancer Center
Transplantation of Reconstructed Renal Allografts Following Ex-Vivo Partial Nephrectomy
Case Comprehensive Cancer Center
Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney Cancer
Ohio State University Comprehensive Cancer Center
Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Renal Cell Carcinoma (RCC) Scramble
M.D. Anderson Cancer Center
Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma
Fox Chase Cancer Center
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
Fox Chase Cancer Center
Multimodal Machine Learning Characterization of Solid Tumors
Massachusetts General Hospital
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
Fox Chase Cancer Center
Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)
M.D. Anderson Cancer Center
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
OHSU Knight Cancer Institute
Neoadjuvant PD-L1 Inhibitor Plus Anlotinib for Kidney Preservation in Complex Renal Cell Carcinoma
RenJi Hospital
DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers
M.D. Anderson Cancer Center
Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
NRG Oncology
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
M.D. Anderson Cancer Center
Moonlanding
Vall d'Hebron Institute of Oncology
Cadonilimab (AK104) Plus Lenvatinib in Previously Immunotherapy-Treated Advanced/Metastatic Clear Cell Renal Cell Carcinoma
RenJi Hospital
Drug Screening Using Novel IMD in Renal Cell Carcinoma
Brigham and Women's Hospital
EXACT
Hoosier Cancer Research Network
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma
M.D. Anderson Cancer Center
EVAX
University Hospital, Bordeaux
A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)
M.D. Anderson Cancer Center
18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
Peking University First Hospital
A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation Therapy
M.D. Anderson Cancer Center
PRO-VISION
UNC Lineberger Comprehensive Cancer Center
CD70-targeted immunoPET Imaging of Malignant Cancers
RenJi Hospital
ITHORinVHL
IRCCS San Raffaele
Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma
Dana-Farber Cancer Institute
Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer
City of Hope Medical Center
TRIPLE-PATH
Jinling Hospital, China
Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy
City of Hope Medical Center
KSD-201 Treatment for Advanced Clear Cell Renal Cell Carcinoma: an Early Exploratory Clinical Study
Kousai Bio Co., Ltd.
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
Fred Hutchinson Cancer Center
PEP-C
Centre Hospitalier Universitaire de Saint Etienne
Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy
Vanderbilt-Ingram Cancer Center
Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer
Emory University